Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Author(s): Sattva S. Neelapu¹;Caron A. Jacobson²;Armin Ghobadi³;David B. Miklos⁴;Lazaros J. Lekakis⁵;Olalekan O. Oluwole⁶;Yi Lin⁷;Ira Braunschweig⁸;Brian T. Hill⁹;John M. Timmerman¹⁰;Abhinav Deol¹¹;Patrick M. Reagan¹²;Patrick Stiff¹³;Ian W. Flinn¹⁴;Umar Farooq¹⁵;Andre H. Goy¹⁶;Peter A. McSweeney¹⁷;Javier Munoz¹⁸;Tanya Siddiqi¹⁹;Alex F. Herrera¹⁹;Julio C. Chavez²⁰;Nancy L. Bartlett²¹;Adrian A. Bot²²;Rhine R. Shen²²;Jinghui Dong²²;Kanwarjit Singh²²;Harry Miao²²;Jenny J. Kim²²;Yan Zheng²²;Frederick L. Locke²⁰

Source: Blood (2023) 141 (19): 2307–2315

Dr. Anjan Patel's Thoughts

5-year survival data from the Zuma trials shows that there is curative potential in r/r DLBCL with cure rates near 50%.

KEY POINTS

Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL. Durable responses were associated with expansion of chimeric antigen receptor T cells early after intravenous infusion.

ABSTRACT

In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we assessed outcomes in ZUMA-1 after 5 years of follow-up. Eligible adults received lymphodepleting chemotherapy followed by axi-cel (2 × 106 cells per kg). Investigator-assessed response, survival, safety, and pharmacokinetics were assessed in patients who had received treatment. The objective response rate in these 101 patients was 83% (58% complete response rate); with a median follow-up of 63.1 months, responses were ongoing in 31% of patients at data cutoff. Median overall survival (OS) was 25.8 months, and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91% of patients. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. This trial was registered at ClinicalTrials.gov, as #NCT02348216.

Author Affiliations

¹Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;²Dana-Farber Cancer Institute, Boston, MA;³Division of Medical Oncology, Washington University School of Medicine, St Louis, MO;⁴Department of Medicine–Med/Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA;⁵Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL;⁶Vanderbilt-Ingram Cancer Center, Nashville, TN;⁷Department of Hematology, Mayo Clinic, Rochester, MN;⁸Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY;⁹Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;¹⁰Division of Hematology and Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA;¹¹Karmanos Cancer Center, Wayne State University, Detroit, MI;¹²Department of Medicine, University of Rochester School of Medicine, Rochester, NY;¹³Loyola University Chicago Stritch School of Medicine, Maywood, IL;¹⁴Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN;¹⁵University of Iowa, Iowa City, IA;¹⁶John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;¹⁷Colorado Blood Cancer Institute, Denver, CO;¹⁸Department of Hematology, Mayo Clinic, Phoenix, AZ;¹⁹Division of Lymphoma, City of Hope National Medical Center, Duarte, CA;²⁰Moffitt Cancer Center, Tampa, FL;²¹Washington University School of Medicine and Siteman Cancer Center, St Louis, MO;²²Kite, a Gilead Company, Santa Monica, CA

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Mosunetuzumab has an impressive response rate and durability of response in heavily pre-treated patients with B-cell NHL. This was presented at our webinar on August 7, 2024 by the cellular therapy team, slides are available upon request. We have this drug available at select sites within our practice so please contact us if you have a patient in mind.

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

For transplant-eligible patients with Mantle Cell Lymphoma, Obinutuzumab showed superior efficacy compared to Rituximab. These patients are uncommon, but the results of this study show that in this context O seems to beat R in every aspect, including a 5-yr PFS of 82.8 vs 66.6%, which is striking. I would consider this option for the appropriate patient.

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

This combination had impressive results but led to a high rate of ventricular arrythmias (9%), hence the combination is not recommended. Another study with the combination and rituximab was also suspended, the etiology of the higher rate of Vent arrhythmias is not known. This combination in another lymphoid malignancies did not lead to that rate of toxicity.

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

This gives more credence to the idea of avoiding bendamustine before CAR T therapy. Patients exposed to bendamustine had about a 20% lower overall response rate (ORR), 50% shorter progression-free survival (PFS) and >50% shorter overall survival (OS) compared to those who were bendamustine naive. Although other factors may also play a role here, these seem to be significant differences and should make it clear that one should not use this drug before pursuing CAR T therapy.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Good review of high-risk patients, showing that prophylactic high dose MTX did not have lower risk of CNS disease.